A Study of Palifosfamide Tris Plus Doxorubicin Versus Doxorubicin in Unresectable or Metastatic Soft-tissue Sarcoma

PHASE2UnknownINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

April 30, 2012

Study Completion Date

April 30, 2014

Conditions
Soft Tissue Sarcoma
Interventions
DRUG

Palifosfamide Tris and Doxorubicin

On Day 1 of each cycle (21 days), 150 mg/m2 IV (intravenous) palifosfamide tris and 75 mg/m2 IV doxorubicin are administered on the same day. Doxorubicin administration will be initiated approximately 60 minutes after the completion of palifosfamide tris dosing. Palifosfamide tris alone is administered on Days 2 and 3, every 3 weeks (one 21-day cycle).

DRUG

Doxorubicin

On Day 1 of each cycle, 75 mg/m2 doxorubicin is administered IV.

Trial Locations (23)

83814

Coeur d'Alene

400015

Cluj-Napoca

Unknown

Santa Monica

Washington D.C.

Tampa

Chicago

Park Ridge

Iowa City

Lenaxa

Albuquerque

New York

Durham

Portland

Philadelphia

Memphis

Nashville

San Antonio

Salt Lake City

Seattle

Milan

Padua

Torino

Lasi

Sponsors
All Listed Sponsors
lead

Alaunos Therapeutics

INDUSTRY